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Abstract
Background: Diabetes mellitus is a major risk factor for prolonged hospital stays, renal failure, and mortality in patients having
coronary artery bypass grafting (CABG). Complications pose a serious threat to patients and prolong intensive care and hospital
stays. Low glomerular filtration rate (GFR) due to existing renal impairment or volume depletion may exacerbate acute renal
impairment/failure in these patients. Preoperative volume replacement therapy (VRT) is reported to increase the GFR and we
hypothesize that VRT will reduce renal impairment and related complications in diabetic patients.
Objective: The objective of this study is to establish the efficacy of preoperative VRT in reducing postoperative complications
in diabetic patients undergoing CABG surgery. Time to “fit for discharge”, incidence of postoperative renal failure, cardiac injury,
inflammation, and other health outcomes will be investigated.
Methods: In this open parallel group randomized controlled trial, 170 diabetic patients undergoing elective or urgent CABG
surgery received 1 mL/kg/hour of Hartmann’s solution for 12 consecutive hours prior to surgery, versus routine care. The primary
outcome was time until participants were “fit for discharge”, which is defined as presence of: normal temperature, pulse, and
respiration; normal oxygen saturation on air; normal bowel function; and physical mobility. Secondary outcomes included:
incidence of renal failure; markers of renal function, inflammation, and cardiac damage; operative morbidity; intensive care stay;
patient-assessed outcome, including the Coronary Revascularization Outcome Questionnaire; and use of hospital resources.
Results: Recruitment started in July 2010. Enrolment for the study was completed in July 2014. Data analysis commenced in
December 2016. Study results will be submitted for publication in the summer of 2017.
Conclusions: VRT is a relatively easy treatment to administer in patients undergoing surgical procedures who are at risk of
renal failure. This experimental protocol will increase scientific and clinical knowledge of VRT in diabetic patients undergoing
elective or urgent CABG surgery. Findings supporting the efficacy of this intervention could easily be implemented in the health
care system.
Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 02159606;
http://www.controlled-trials.com/ISRCTN02159606 (Archived by WebCite at http://www.webcitation.org/6rDkSSkkK)
(JMIR Res Protoc 2017;6(6):e119)   doi:10.2196/resprot.7386
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Introduction
Diabetes mellitus (DM) has been recognized as a major risk
factor for atherosclerosis [1,2], and its prevalence is on the rise
due to an increasingly aging and obese population [3]. DM is
also a major risk factor for postoperative renal failure, infections,
and in-hospital and late mortality in patients undergoing
coronary artery bypass grafting (CABG) surgery [4,5]. Diabetic
patients currently represent approximately 20% of all patients
undergoing CABG surgery [3,4,6-8]. This rate does not include
undiagnosed DM, which has been reported to be 5.2% of all
patients admitted for CABG [6]. In keeping with the United
Kingdom (UK) average, approximately 20% of CABG patients
have a diagnosis of DM on admission at our institution [4].
However, we have previously demonstrated that only 40% of
patients experiencing postoperative moderate-to-poor blood
sugar control after CABG were diagnosed as having DM prior
to surgery [9]. This finding suggests that the prevalence of
undiagnosed DM in patients admitted for CABG may be grossly
underestimated, and emphasizes the importance of optimizing
the perioperative management of these patients.
Renal insufficiency and acute kidney injury (AKI) remain
frequent and serious complications following cardiac surgery,
and are associated with other postoperative complications,
mortality, prolonged hospital stays, and costs [7-9]. AKI
following CABG is also consistently associated with DM [7-9].
Our group has demonstrated that DM is an independent predictor
of renal insufficiency in a large cohort study [9], consistent with
previous reports linking DM with AKI [8]. AKI can be defined
in various ways. The introduction of the Risk, Injury, Failure,
Loss, and End stage (RIFLE) criteria have standardized the
National Health Service (NHS) definition of AKI and allowed
more objective comparisons between different studies [10]. In
its most severe form, AKI requires dialysis [10-12]. Death is
7-8 times more frequent in patients requiring dialysis because
of AKI [13], but less severe renal dysfunction is also strongly
associated with mortality [14]. AKI is reported to be more
common after CABG in diabetic patients compared to
nondiabetic patients [6,9].
Body fluid volume depletion may also be prevalent in patients
undergoing CABG, especially diabetics. One factor leading to
volume depletion is preoperative use of diuretics, which can
cause hypovolemia, which reduces cardiac preload, cardiac
output, and related organ perfusion. In addition, the use of
vasodilators can also lead to relative volume depletion and
hypotension [15]. Diminished renal perfusion can be a
consequence of volume depletion, and of hemodynamic changes
associated hypovolemia or with impaired left ventricular
function [15,16]. In addition, agents such as nonsteroidal
antiinflammatory drugs, cyclosporine, angiotensin-converting
enzyme inhibitors, and angiotensin II receptor blockers can
decrease renal perfusion [17-19]. In these situations, the resultant
diminution in renal blood flow and estimated glomerular
filtration rate (eGFR) can lead to postoperative renal
insufficiency, and surgical patients could benefit from mild
preoperative fluid replacement therapy since this has been
associated with an increase in GFR [20]. A reduced eGFR may
simply be a reflection of ongoing baseline renal impairment,
which is also typical of diabetic patients.
Isotonic crystalloid solutions, such as Hartmann’s solution, are
the first choice for volume replacement therapy (VRT) [21].
Unlike plasma expanders, crystalloid solutions have no
nephrotoxic (or other specific) side-effects [21]. Isotonic
crystalloid solutions are distributed rapidly into the tissue
interstitial compartment and have a half-life of 20-30 minutes
in the intravascular space.
This study protocol seeks to examine the effects of preoperative
gentle VRT on postoperative time to “fitness for discharge”,
renal failure, inflammation, cardiac injury, postoperative
complications, and mortality in diabetic patients undergoing
CABG surgery. A definitive trial of VRT in this indication is
required before this relatively easy-to-administer treatment can
be proposed as adjuvant therapy in diabetic patients undergoing
cardiac surgery, or indeed other major surgical procedures. We
hypothesize that the postoperative incidence of renal failure will
be lower, and postoperative recovery faster, in diabetic patients
treated with gentle VRT prior to surgery.
The main objective of the Volume Replacement in Diabetic
Patients Undergoing Coronary Artery Bypass Grafting Surgery:
Protocol for a Randomized Controlled Trial (VeRDiCT) is to
evaluate the effect of VRT versus routine care on time until
participants are “fit for discharge”, which is defined as normal
temperature, pulse, respiratory rate, oxygen saturation on air,
bowel function, and physical mobility. Secondary objectives
will be to evaluate the effect of VRT versus routine care on the
incidence of: postoperative renal failure and biochemical serial
markers of renal function, inflammation, and cardiac damage;
operative morbidity; intensive care stay; and use of hospital
resources. In addition, we will evaluate patient-assessed
outcome, which will be based on the serial administration of
the Coronary Revascularization Outcome Questionnaire
(CROQ).
We are conducting an open, parallel group, randomized
controlled trial (RCT) in which diabetic elective or urgent
patients undergoing CABG surgery will receive VRT or routine
care. This treatment has already been shown to prevent AKI in
certain clinical scenarios [21]. The most likely mechanism of
action of VRT is by increasing eGFR [20]. It has also been
suggested that VRT is essential to obtain adequate systemic
circulation and microcirculation [22].
Methods
Type of Clinical Trial
This is an open, parallel group, RCT of preoperative VRT with
Hartmann’s solution versus routine care in diabetic patients
undergoing CABG. The trial is not blinded, as it is not possible
to mask the infusion of the Hartmann’s solution. A covered drip
could have been set up for all trial patients but it would still be
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obvious to the patient and those responsible for their care
whether or not a fluid infusion was being given.
Study Setting
This study was conducted in Bristol, UK at the Bristol Heart
Institute, University Hospital Bristol NHS Foundation Trust. A
parallel study was run at Rabindranath Tagore International
Institute of Cardiac Sciences (RTIICS), Kolkata, India. The
results of both trials are being combined and recruitment at both
sites has contributed to the target sample size. RTIICS was
responsible for research governance and approvals of their study.
Ethical Review
The University Hospital Bristol NHS Foundation Trust has
sponsored the trial in the UK. The trial was approved by the
North Somerset & South Bristol Research Ethics Committee
(REC; reference 10/H0106/1) in February 2010 in the UK. The
study is a Clinical Trial of an Investigational Medicinal Product
(IMP) and was approved by the UK Medicines and Healthcare
Products Regulatory Agency (MHRA) in 2010. The study is
registered (ISRCTN 02159606).
Participants
For this study, 170 diabetic patients undergoing CABG surgery
were recruited to the two parallel studies according to the flow
chart shown in Figure 1.
Figure 1. Study flow chart.
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Participant Recruitment
To assess eligibility, a member of the local research team (study
clinician/research nurse/trial coordinator) in collaboration with
the chief investigator (CI) has assessed patients’ medical notes
to assess eligibility. VRT can be used in most adult diabetic
patients for whom CABG is planned. Therefore, all diabetic
adults aged >16 years and <80 years having elective or urgent
isolated CABG for the first time represented the target study
population. Participants could enter the study if all of the
following applied: (1) patient was diagnosed with type I or type
II diabetes, treated with oral medication and/or insulin (ie, not
diet controlled only); (2) aged >16 and <80 years; (3) underwent
elective or urgent isolated first-time CABG; (4) left ventricular
ejection fraction >30%. Participants were excluded from the
study if they had: (1) undergone previous cardiac surgery; (2)
emergency or salvage operation; (3) chronic renal failure
requiring dialysis; (4) current congestive heart failure; (5) left
ventricular ejection fraction <30%.
Information and Consent
Potential trial participants were identified from CABG waiting
lists (elective patients) and theatre schedules (urgent patients).
All potential participants were sent or given an invitation letter
and Patient Information Sheet (PIS) approved by the REC,
which described the study. The patient was given time to read
the PIS and to discuss their participation with others outside the
research team (eg, relatives or friends) if they wished. Most
patients had at least 24 hours to consider whether they would
participate. In a few cases this time interval was shorter (eg, for
patients admitted for urgent surgery without prior notification
to the waiting list coordinator). Details of all patients approached
for the trial and reason(s) for nonparticipation (eg, reason for
being ineligible or patient refusal) were documented. Signed
informed consent was required and taken from all eligible
patients who were willing to participate.
Study Medication
Hartmann’s solution is classed as an IMP and is therefore under
the regulation of the MHRA. The IMP was only administered
to patients randomized to the VRT arm (there was no placebo).
The dosage of the solution is dependent on body mass as
follows: 1mL/kg/hour for 12 hours; therefore, maximum dose
(mL) = body mass x 12.
Study medication was stored at room temperature in a
temperature-monitored lockable cupboard. If the surgery was
delayed and rescheduled to take place the next calendar day
(morning or afternoon slot), the intervention was not to be
repeated. If the surgery was delayed for 2 days or more, the
intervention was repeated, and the IMP was represcribed.
Procedure
Patients were randomly assigned in a 1:1 ratio using an
Internet-based randomization system (Sealed Envelope Ltd).
Cohort minimization was used to achieve balance between
groups. Random allocations were generated by computer once
the relevant baseline data required to identify the patient and
establish eligibility were entered into the system. Consented
patients were randomized in the evening on the day of
admission, with the VRT intervention delivered overnight prior
to surgery. If the operation was unexpectedly rescheduled, the
patient retained their study number and randomized allocation.
There was no requirement to have code breaking procedures in
place. The trial was unblinded and the treatment was recorded
in the medical notes and on the fluid chart.
Participants were randomly assigned to receive either VRT (1
mL/kg/hour of Hartmann’s solution for 12 consecutive hours
prior to surgery) or usual care (no additional preoperative fluids).
Both groups were fasted for 6 hours prior to surgery. At surgery,
patients were managed according to routine anesthetic, surgical,
and perfusion standards. Undertaking of coronary surgery with
or without cardiopulmonary bypass and cardioplegic arrest were
performed according to the surgeon’s preference. All other
aspects of the patient’s preoperative and postoperative
management were in accordance with existing protocols in use.
The VRT was the only intervention administered over and above
the usual care. Participants were asked to donate small blood
and urine samples before, during, and after surgery, as well as
any leftover tissue available during surgery that would normally
be discarded. At discharge, participants were asked to indicate
how they felt about their readiness to go home. At 6-8 weeks
postsurgery, participants were asked to complete a telephone
assessment of their wounds to ascertain presence of infection
and answer a question regarding readmissions. Wounds were
assessed using a recognized quantitative scoring method that
provides a numerical score related to the severity of wound
infection using objective criteria, including additional treatment,
serous discharge, erythema, purulent exudate, separation of the
deep tissues, isolation of bacteria, and the duration of inpatient
stay (ASEPSIS). Three months after surgery, participants were
asked to complete the CROQ. Key data collection points are
shown in Table 1.
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Table 1. Key data collection points of measured outcomes.
3 months6-8 weeksDischargeDay 5Day 4Day 3Day 2Day 1Day of
surgery
Pre-surgery
✓Eligibility
✓Written consent
✓Randomized allocation
✓Demographics and past
medical history
✓✓✓✓✓
✓
(24, 36
hours)
✓
✓
(0, 12
hours)
✓Blood for serum creatinine
(AKI/ eGFR) and other bio-
chemical predictors of
health outcome
✓Operative details
✓Clinical outcomes
✓✓CROQ
✓Readiness for discharge
✓✓✓ASEPSIS wound inspection
✓ASEPSIS post-discharge
surveillance
✓✓✓Resource use data
✓✓✓✓✓Urine sample (renal
glomerular and tubular in-
jury, microRNA and other
biochemical predictors of
health outcome)
✓
(prior to
chest open-
ing)
Blood for fasting glucose
and hemoglobin A1c
✓✓✓✓Blood for serum and plasma
microRNA
✓
(intra-oper-
atively)
Leftover material/specimens
collected during surgery
✓✓✓✓✓
✓
(0, 12
hours)
✓Blood for Troponin T
✓✓✓✓✓
✓
(0, 12
hours)
✓Blood for C-reactive protein
Results
Primary Outcome
The primary outcome is the time until patients are classified as
“fit for discharge”, since prevention of renal impairment by the
proposed intervention is expected to impact the risk of many
postoperative complications. A patient must have normal
temperature, pulse, respiratory rate, oxygen saturation on air,
and bowel function and be physically mobile (taking into
account preoperative mobility such as wheel chair use) in order
to be classified as “fit for discharge”.
Secondary Outcomes
Secondary outcome measures include: (1) measurements of
serum creatinine from blood samples collected preoperatively
and postoperatively; (2) microalbumin/creatinine ratio measured
in urine samples collected preoperatively and postoperatively;
(3) N-acetyl-beta-D-glucosaminidase release measured in urine
samples collected preoperatively and postoperatively; (4)
participants’ judgement about readiness for discharge; (5)
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in-hospital mortality and morbidity; (6) use of health care
resources; (7) health-related quality of life as measured by the
CROQ; (8) preoperative fasting blood glucose; (9)
micro-ribonucleic acid (RNA) measured in preoperative and
postoperative urine, serum, and plasma samples; (10) C-reactive
protein (CRP) measured preoperatively and postoperatively;
and (11) serial troponin T release measured preoperatively and
postoperatively. Measures 8-11 were only included in a
subgroup of the UK trial.
Safety Reporting
Side Effects
No previous randomized trials of VRT during cardiac surgery
have been carried out, or were ongoing, at the time of the study.
Hartmann’s solution is widely used for VRT, and is not known
to cause allergic reactions or hemodynamic instability in this
patient group. In this study, the solution was given at a very
slow rate to have minimal impact on the well-being of the patient
preoperatively. The solution was administered via a peripheral
line that the patient would always have inserted at some point
during their admission, so this was not considered to pose any
additional risk.
Withdrawal of Individual Participants
Participants could withdraw from the study at any time for any
reason and without any sanction. Researchers, after consulting
with the CI and the study coordinator, could also interrupt the
treatment program if, in their opinion, continuing the treatment
may affect the patient’s welfare.
Suspension of the Study
In cases of suspected severe adverse events related to the
administration of the treatment, the study could be interrupted
and the researchers and coordinator would decide whether to
continue.
Reporting of Adverse Events
Adverse events were recorded from the randomization time
point, throughout the duration of the participant’s postoperative
hospital stay, and for the predefined 3-month follow-up period.
Any adverse event spontaneously reported by the participant,
or observed by the researcher or the research team, was be
recorded on the case report form (CRF) that was designed for
this purpose. Events were also reported in accordance with the
International Conference for Harmonization of Good Clinical
Practice guidelines and followed the sponsor’s policy for safety
reporting. Expected events included those related to
administering Hartmann’s solution, as well as complications
associated with cardiac surgery.
Anticipated Benefits
Potential benefits to participants include the possibility of
improved renal protection for the intervention group, which we
hypothesize will lead to a reduced incidence of postoperative
renal insufficiency and a faster postoperative recovery. Should
our hypothesis be supported by the findings of the trial, all future
diabetic patients undergoing CABG should benefit from
preoperative volume replacement. The main benefit to society
is the provision of high quality evidence to address this
important area of clinical uncertainty.
Data Analysis
Sample Size
There were no previous trials of VRT in diabetics, hence no
data to guide the likely target difference in renal function to be
observed for the purpose of sample size calculation. No
published data existed for the primary outcome of “fit for
discharge” (chosen to minimize biases that can affect standard
data on postoperative length of stay) and the sample size
calculation described here uses information about actual
postoperative length of stay as a proxy for the primary outcome.
The median postoperative stay for diabetic patients having
CABG (from our institutional database) is 7 days. Assuming
time to “fit for discharge” is shorter than actual stay, we have
proposed that the trial should be able to detect a 25% difference
in the proportion of patients “fit for discharge” at 6 days between
VRT and usual care groups (ie, 75% vs 50%). We have proposed
that 170 participants would be required to detect this target
difference with 90% power and 5% significance (2-tailed).
Statistical Analyses
Time to “fit for discharge” and length of Intensive Care Unit
and postoperative hospital stays will be analyzed as
time-to-event data using regression modelling for survival data.
Means for continuous outcomes (transformed logarithmically
if required) will be compared using regression modelling,
adjusting for baseline covariates where available; “mixed
models” will be used for outcomes with repeated measures such
as eGFR and markers of glomerular, tubular, renal function,
microRNA, CRP, and troponin T. Findings will be reported as
effect sizes with 95% confidence intervals. The frequencies of
complications and conversions will be tabulated descriptively.
Analyses will be based on the intention-to-treat (as treated
compared to intention-to-treat); conversions are expected to be
rare.
A subgroup analysis comparing trial-specific (eg, UK or India)
primary and secondary biochemical marker outcomes is
prespecified in the statistical analysis plan. Subgroups will be
compared by adding an allocation by trial interaction term into
the model.
Trial Status
Of the 491 patients assessed for eligibility during the study
period, 169 patients (120 in UK, 49 in India) were successfully
recruited and randomized over a 48-month period. Study
recruitment was closed in July 2014. Study results are expected
to be published in the summer of 2017.
Discussion
Principal Findings
The VeRDiCT study offers a unique opportunity to answer a
fundamental question about a clinical intervention, which could
reduce postoperative complications in an increasing proportion
of atherosclerotic diabetic patients. To the best of our
knowledge, at the time of study design there were no other
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ongoing trials investigating the clinical benefit of VRT in
diabetic patients undergoing coronary surgery. To investigate
the potential clinical efficacy of VRT, it is necessary to
undertake a well-designed RCT to assess the impact of VRT
on renal function and health outcomes in the selected patient
cohort. The proposed research should contribute significantly
to the understanding of the role of VRT in reducing
postoperative complications in diabetic patients undergoing
surgery and, if successful, contribute significantly to improving
health care while reducing the burden on hospital resources. A
multi-dimensional methodological approach based on the
evaluation of an extensive list of objective and serial clinical,
biochemical, and functional measures should prove valuable in
characterizing the effects of VRT. Studying serial biochemical
markers of renal and cardiac injury (and of inflammatory
activation) at baseline, during surgery, and postoperatively might
provide evidence for an organ-specific impact of VRT, which
in turn should translate into health outcome benefits. In
particular, a reduction in renal failure should affect the primary
outcome of time to “fitness for discharge”. The methods used
in this trial to assess renal, myocardial, and inflammatory
function and activation have traditionally been employed in
cardiac surgery and in diabetic patients [2-5,9].
Following discussion during the study design period, it was
decided that the trial was not going to be blinded, as it was not
practically possible to mask the infusion of the Hartmann’s
solution. A covered drip could have been set up for all trial
patients but it would have still been obvious to the patient and
those responsible for their care whether or not a fluid infusion
was being given. In addition, the prescription would have been
visible in the medical record. However, the outcome endpoints
of the trial are based on objective measures, hence the influence
of the lack of blinding is minimal.
In undertaking this trial, the study team have encountered a
number of logistical problems that reflect the difficulty of
conducting research within a routine setting. The first was the
variability of the information supplied to our institution (a
tertiary referral center for cardiac surgery) upon referral of the
patient. This variable made it difficult to establish which patients
were diabetic, and this delay reduced the time available to
approach the patient about the study, and for the patient to
consider their participation. This issue was particularly
problematic for urgent inpatients transferred directly from
another hospital, often with very short notice. In these latter
cases, this problem also had an impact on delivery of the
intervention. The study was further hampered by the introduction
of a Day of Surgery Admission (DOSA) policy implemented
during the recruitment phase. The DOSA policy imposed a
system by which elective patients would be preadmitted for a
few hours for baseline evaluations two weeks before surgery,
and were no longer admitted the evening before surgery, but on
the morning of surgery. Patients admitted as DOSA could not
be given the intervention, as there was not enough time to
administer the 12-hour infusion of VRT. The study team was
able to work with the waiting list coordinators to admit potential
trial patients the night before surgery, but pressure on beds
meant that this was not always possible.
The trial was conceived in Bristol, UK. The study design and
protocol were discussed and agreed between the two trial teams
following a preparatory visit to Kolkata by the UK CI. To
enhance consistency across the trials, the Indian trial used the
same protocol, study documents, and CRFs as the UK team.
The Indian trial also used Sealed Envelope Ltd for
randomization.
During the recruitment phase, there were two amendments to
the study protocol. The first one consisted of removing the fixed
12-hour cap that allowed the patient to consider entering the
trial; this was done to allow the inclusion of urgent inpatients
referred at short notice from other hospitals. Inclusion of these
patients is important to ensure that study results are generalizable
to the study population that is likely to benefit from the
intervention. Patients were only consented if they felt that they
had had enough time to consider their participation. A second
amendment (for a sub-cohort of patients) consisted of expanding
the list of outcome measures, including a measure of baseline
fasting glucose, an extra time point for sampling of blood and
urine, and inclusion of microRNA, CRP, and troponin I as extra
biochemical markers.
Limitations
This is the first trial assessing the efficacy of preoperative VRT
in diabetic patients undergoing coronary surgery on
postoperative renal function and health outcomes. There are,
however, some potential limitations: (1) only one dose of VRT
was administered; (2) only the elective and urgent patient
population was studied; and (3) logistical difficulties, such as
the introduction of the DOSA policy, meant that patients
otherwise eligible were not included. Future investigations
should seek to determine the effects of higher doses of VRT,
and doses that are administered during the postoperative period
in these patients.
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